{
    "clinical_study": {
        "@rank": "30014", 
        "arm_group": [
            {
                "arm_group_label": "solifenacin succinate", 
                "arm_group_type": "Active Comparator", 
                "description": "Solifenacin succinate, 5mg or 10 mg once daily"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Drug: Placebo oral"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine if Vesicare (Solifenacin succinate) is effective\n      in treating over-active bladder symptoms during radiation therapy of the prostate."
        }, 
        "brief_title": "VESIcare For Improving OAB Symptoms in Patients Undergoing IGRT of the Prostate", 
        "completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Over-Active Bladder", 
        "condition_browse": {
            "mesh_term": "Urinary Bladder, Overactive"
        }, 
        "detailed_description": {
            "textblock": "This is a randomized double blind placebo controlled flexible dose 12 week study. Following\n      screening, subjects will receive their first dose of study medication following completion\n      of AUASS questionnaire on the first day of radiation treatment (baseline) and will continue\n      for twelve weeks. Subjects will be started on 5 mg of study medication.  The AUASS will be\n      completed at baseline, weeks 4, 8 and 12. A 16 week visit conducted over a phone interview."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved written\n             Informed Consent and privacy language as per HIPAA Authorization for the USA test\n             sites is obtained from subject or legally authorized representative prior to the\n             initiation of  this study (including withdrawal of prohibited medication, if\n             applicable)\n\n          2. Subject must be an ambulatory male at least 18 years of age.\n\n          3. Subject has been diagnosed with prostate carcinoma and has elected to undergo\n             external beam radiation therapy.\n\n          4. Subject is willing to complete the American Urology Association Symptom Score (AUASS)\n             Questionnaire.\n\n        Exclusion Criteria:\n\n          1. Subject has undergone a prostatectomy\n\n          2. Subject exhibits symptoms of urinary tract infection.\n\n          3. Subject exhibits severe neurologic damage or has undergone prostatectomy.\n\n          4. Subject diagnosed with OAB and is being treated with medication for alleviation of\n             OAB symptoms within 12 months prior to the Screening Visit.\n\n          5. Subject has evidence of uncontrolled narrow angle glaucoma, urinary or gastric\n             retention, neurogenic bladder; prostatitis, or persistent UTI.\n\n          6. Subject exhibits hypersensitivity to Solifenacin succinate, any ingredients, or other\n             anticholinergic agents.\n\n          7. Subject has undergone treatment with any investigational drug within 30 days prior to\n             screening procedure.\n\n          8. Subject has exhibited history of diagnosed gastrointestinal obstructive disease.\n\n          9. Subjects with co-morbid lower urinary tract symptoms (LUTS).\n\n         10. Subjects exhibiting clinically significant bladder outflow obstruction (BOO).\n\n         11. In the opinion of the Study Investigator, the patient has exhibited prior to the\n             screening or Baseline visit, a clinically significant disease or medical condition\n             that would exclude the subject from participating in the study.\n\n         12. Subjects who have received prior pelvic radiation.\n\n         13. Subjects with history of severe hepatic impairment.\n\n         14. Subjects with history of Congenital or Acquired QT prolongation."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 24, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01777217", 
            "org_study_id": "VESI-12J03"
        }, 
        "intervention": [
            {
                "arm_group_label": "solifenacin succinate", 
                "intervention_name": "Solifenacin succinate", 
                "intervention_type": "Drug", 
                "other_name": "VESIcare"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Quinuclidin-3'-yl-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate monosuccinate"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Urination Disorder", 
            "Overactive Bladder", 
            "Prostate Cancer Radiation", 
            "Vesicare"
        ], 
        "lastchanged_date": "March 6, 2013", 
        "location": [
            {
                "contact": {
                    "last_name": "Emily Cruz, RN", 
                    "phone": "720-214-6500"
                }, 
                "facility": {
                    "address": {
                        "city": "Greenwood Village", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80111"
                    }, 
                    "name": "Century Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Barry Blyton, MD", 
                    "role": "Sub-Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Starr Walker", 
                    "phone": "713-630-8181"
                }, 
                "contact_backup": {
                    "last_name": "Rokisha Howard", 
                    "phone": "713-630-8181"
                }, 
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77025"
                    }, 
                    "name": "Century Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Sanjay Mehta, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Pilot Study to Assess the Safety and Efficacy of Solifenacin (VESIcare) for Improving Urinary and Bladder Functions in Patients Undergoing Radiation Therapy of the Prostate", 
        "overall_contact": {
            "email": "rking@advancedresearchnetwork.com", 
            "last_name": "Rima King, BS, CCRP", 
            "phone": "832-681-8740"
        }, 
        "overall_official": {
            "affiliation": "Century Cancer Centers", 
            "last_name": "Sanjay Mehta, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change from baseline to end of study measured by the American Urology Association Symptom Score Questionnaire (AUASS).", 
            "safety_issue": "Yes", 
            "time_frame": "baseline  and 12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01777217"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Advanced Research Network", 
        "sponsors": {
            "collaborator": {
                "agency": "Astellas Pharma US, Inc.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Advanced Research Network", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2013"
    }
}